Abstract
Membrane-bound complement regulatory proteins (mCRPs) play an important role in the protection of cells from complement-mediated injury. It is now apparent that malignant tumor cells also express these proteins to escape complement attack. Here, Arko Gorter and Seppo Meri discuss the implications of complement resistance for the immunotherapeutic treatment of solid tumors with monoclonal antibodies.
Publication types
-
Research Support, Non-U.S. Gov't
-
Review
MeSH terms
-
Animals
-
Antibodies, Monoclonal / therapeutic use
-
Antibody-Dependent Cell Cytotoxicity
-
Antigens, CD / physiology
-
CD55 Antigens / physiology
-
CD59 Antigens / physiology
-
Complement Activation
-
Complement Membrane Attack Complex / immunology
-
Complement System Proteins / physiology*
-
Cytotoxicity, Immunologic*
-
Humans
-
Immunotherapy
-
Membrane Cofactor Protein
-
Membrane Glycoproteins / physiology
-
Membrane Proteins / physiology*
-
Mice
-
Mice, Nude
-
Neoplasm Proteins / physiology*
-
Neoplasms / immunology*
-
Neoplasms / therapy
-
Neoplasms, Experimental / immunology
-
Neoplasms, Experimental / therapy
-
Receptors, Complement 3b / physiology
Substances
-
Antibodies, Monoclonal
-
Antigens, CD
-
CD46 protein, human
-
CD55 Antigens
-
CD59 Antigens
-
Complement Membrane Attack Complex
-
Mcp protein, mouse
-
Membrane Cofactor Protein
-
Membrane Glycoproteins
-
Membrane Proteins
-
Neoplasm Proteins
-
Receptors, Complement 3b
-
Complement System Proteins